NEW YORK (GenomeWeb) – ArcherDx has announced a global co-marketing and distribution agreement with Illumina for its FusionPlex oncology research products.
Under the terms of the non-exclusive agreement, Illumina will market and promote the assays outside the US. Boulder, Colorado-based ArcherDx will continue to sell its products directly in the US market.
"It was a natural progression to expand our strategic alliance with Illumina and access their global sales channels," ArcherDx CEO Jason Myers said in a statement, noting that the combination of the company's reagents and Illumina's sequencing platform has been adopted at cancer centers, reference labs, and pharmaceutical companies. "Archer's continued success is no longer a function of technology development, but is a matter of global commercial scale," he said.
Last week, the firms announced a deal to collaborate on development of in vitro diagnostics based on ArcherDx's anchored multiplex PCR chemistry for Illumina's MiSeqDx instrument. ArcherDx also has a co-marketing agreement with GenomOncology.